5HHV | pdb_00005hhv

Inhibiting complex IL-17A and IL-17RA interactions with a linear peptide.

Liu, S.,&nbspDesharnais, J.,&nbspSahasrabudhe, P.V.,&nbspJin, P.,&nbspLi, W.,&nbspOates, B.D.,&nbspShanker, S.,&nbspBanker, M.E.,&nbspChrunyk, B.A.,&nbspSong, X.,&nbspFeng, X.,&nbspGriffor, M.,&nbspJimenez, J.,&nbspChen, G.,&nbspTumelty, D.,&nbspBhat, A.,&nbspBradshaw, C.W.,&nbspWoodnutt, G.,&nbspLappe, R.W.,&nbspThorarensen, A.,&nbspQiu, X.,&nbspWithka, J.M.,&nbspWood, L.D.

(2016) Sci Rep&nbsp6: 26071-26071

• PubMed:&nbsp27184415&nbspSearch on PubMedSearch on PubMed Central
• DOI:&nbsphttps://doi.org/10.1038/srep26071
• Primary Citation of Related Structures: &nbsp
  5HHV, 5HHX


• PubMed Abstract:&nbsp
  

  IL-17A is a pro-inflammatory cytokine that has been implicated in autoimmune and inflammatory diseases. Monoclonal antibodies inhibiting IL-17A signaling have demonstrated remarkable efficacy, but an oral therapy is still lacking. A high affinity IL-17A peptide antagonist (HAP) of 15 residues was identified through phage-display screening followed by saturation mutagenesis optimization and amino acid substitutions. HAP binds specifically to IL-17A and inhibits the interaction of the cytokine with its receptor, IL-17RA. Tested in primary human cells, HAP blocked the production of multiple inflammatory cytokines. Crystal structure studies revealed that two HAP molecules bind to one IL-17A dimer symmetrically. The N-terminal portions of HAP form a β-strand that inserts between two IL-17A monomers while the C-terminal section forms an α helix that directly blocks IL-17RA from binding to the same region of IL-17A. This mode of inhibition suggests opportunities for developing peptide antagonists against this challenging target.

  &nbspView More

---

Organizational Affiliation:&nbsp

Worldwide Research and Development, Pfizer Inc., Eastern Point Road, Groton, CT 06340 USA.